Tarsa picks up $10M to get its osteoporosis pill to the FDA

Philadelphia's Tarsa Therapeutics has nailed down a $10 million credit facility to help bankroll an FDA submission for Ostora, the company's treatment for postmenopausal osteoporosis. The money, courtesy of Oxford Finance and Square 1 Bank, will help get Tarsa's lead drug in the hands of regulators, and the biotech expects to file its application in early 2015. In a Phase III trial, the drug proved itself superior to both placebo and nasal calcitonin spray in improving bone density at 48 weeks, Tarsa said. More